Structure-activity Analysis of Taxane-based Broad-spectrum Multidrug Resistance Modulators

Anticancer Research

Volumn 24, Issue 2 A, 2004, Pages 409-415

  Brooks, Tracy A ^a   Kennedy, Daniel R ^a   Gruol, Donald J ^b   Ojima, Iwao ^c   Baer, Maria R ^a   Bernacki, Ralph J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b SIDNEY KIMMEL CANCER CENTER   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Breast cancer resistance protein; Modulation; Multidrug resistance; Multidrug resistance protein; P glycoprotein; Structure activity analysis; Taxane

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; GLYCOPROTEIN P; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; ORTATAXEL; PACLITAXEL; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; CANCER RESISTANCE; CONFERENCE PAPER; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROCESS DESIGN; PROCESS OPTIMIZATION; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LINEAR MODELS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TAXOIDS;

EID: 2442446415     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (38)

1. Schiff PB: Taxol stabilized microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565, 1980.
2. Horwitz SB: Taxol: mechanisms of action and resistance. Ann NY Acad Sci 466: 733-744, 1986.
3. Schibler MJ: Taxol-dependent mutants of chinese hamster ovary cells with alterations in alpha- and beta-tubulin. J Cell Biol 102: 1522-1531, 1986.
4. Kaye S: Tumour cell resistance to anthracyclines: a review. Can Chem Pharm 14: 96-103, 1985
5. Kasimir-Bauer S: Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia. Exp Hematol 30: 1302-1308, 2002.
6. Dean M: The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11: 1156-1166, 2001.
7. Dano K: Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 323: 466-483, 1973.
8. Dano K: Cross resistance between vinca alkaloids and anthracyclines in Ehrlich ascites tumor in vivo. Cancer Chem Rep 56: 701-708, 1972.
9. Vredenburg MR: Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance. J Natl Can Inst 93: 1234-1245, 2001.
10. Minderman H: Multidrug resistance (MDR) modulation by the taxane derivatives IDN-5109 and tRA96023: Effects on P-glycoprotein (Pgp)-, multidrug resistance protein (MRP-1)-, and breast cancer resistance protein (BCRP)-mediated drug transport. Proc Am Assoc Can Res 43: 950, 2002.
11. Brooks TA: Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Can Ther in press, 2003.
12. Honjo Y: Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61: 6635-6639, 2001.
13. Soule HD: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409-1416, 1973.
14. Gollapudi S: Lack of reversal of daunorubicin resistance in HL60/AR cells by cyclosporin A. Anticancer Res 12: 2127-2132, 1992.
15. Minderman H: Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry 48: 59-65, 2002.
16. Fairchild CR: Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Can Res 47: 5141-5148, 1987.
17. Paumi CM: Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-delta(12,14) prostaglandin J(2) in MCF7 breast cancer cells. Biochem 42: 5429-5437, 2003.
18. Doyle LA: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95: 15665-15670, 1998.
19. Speth PA: Quantitation of anthracyclines in human hematopoietic cell subpopulations by flow cytometry correlated with high pressure liquid chromatography. Cytometry 6: 143-150, 1985.
20. Young IT: Proof without prejudice: use of the Kolmogorov-Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem 25: 935-941, 1977.
21. Skehan P: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
22. Attallah AM: A simple highly sensitive methods for the determination of cell viability an electronic particle analyzer, Coulter counter. J Immunol Methods 41: 155-162, 1981.
23. Attallah AM: ADCC analysis with the Coulter counter: a highly sensitive, ultramicro assay suitable for clinical and experimental application. J Immunol Methods 43: 121-129, 1981.
24. Holford NH: Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6: 429-453, 1981.
25. Marquardt DW: An algorithm for least squares estimation of nonlinear parameters. J Soc Ind Appl Math 11: 431-441, 1963.
26. Nash JC: Compact Numerical Method for Computers: Linear Algebra and Function Minimization. New York: John Wiley & Sons, 1979.
27. Gruol DJ: The use of a novel taxane-based P-glycoprotein inhibitor to identify mutations that alter the interaction of the protein with paclitaxel. Mol Pharmacol 60: 104-113, 2001.
28. Borst P: The multidrug resistance protein family. Biochim Biophys Acta 1461: 347-357, 1999.
29. Litman T: From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58: 931-959, 2001.
30. Gruol DJ: Evidence for the locations of distinct steroid and vinca alkaloid interaction domains within the murine mdrlb P-Glycoprotein. Molec Pharm 62: 1238-1248, 2002.
31. Larson RA: Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia? Leukemia 17: 488-491, 2003.
32. Baer MR: Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100: 1224-1232, 2002.
33. List AF: Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98: 3212-3220, 2001.
34. Tan B: Multidrug resistance transporters and modulation. Curr Opin Oncol 12: 450-458, 2000.
35. Litman T: From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58: 931-959, 2001.
36. Hendrikse NH: A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Can Res 59: 2411-2416, 1999.
37. Decleves X: Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int J Cancer 98: 173-180, 2002.
38. Serra M: Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin One 21: 536-542, 2003.